Company intelligence / Profile preview
Ironwood Pharmaceuticals
Boston, Massachusetts, United Statesironwoodpharma.com ↗
- Ownership
- Public · IRWD
- Development stage
- Commercial
01
Overview
Ironwood has a commercialized drug LINZESS® (linaclotide) for IBS-C and CIC in adults and functional constipation in pediatric patients ages 6-17. They are also developing apraglutide, a next-generation GLP-2 analog for short bowel syndrome patients dependent on parenteral support, which requires a confirmatory Phase 3 trial as requested by the FDA in April 2025.
- Therapeutic areas
- Gastroenterology
- Modalities
- Small moleculessynthetic peptides (GLP-2 analog)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
AllerganAstellas
04
Financials
- Market cap
- $665.9M
- Total revenue
- $296.2M
- Enterprise value
- $602M
Beyond the preview
Go deeper on Ironwood Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ironwood Pharmaceuticals.